Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs ...

Facing pressure from the Inflation Reduction Act (IRA) and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO ...

Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent ...

According to Neurocrine, the site is aimed at teenagers and adults with CAH, as well as their caregivers, the parents of ...

After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to ...

In Merck’s quarterly conference call on Thursday, it took CEO Rob Davis less than a minute to tout newly approved pulmonary ...

Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to ...

And the endorsement has come for an oral antibiotic that has been available in Europe for more than 40 years. It’s an odd set ...

Dr. Reddy’s issued a voluntary recall of six lots of sapropterin dihydrochloride powder used to treat phenylketonuria (PKU) ...

It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration ...

While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large ...

A Chiesi survey has found widespread unmet needs among Fabry disease patients taking drugs such as Sanofi’s Fabrazyme, ...